Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1653 1657
This examiner grants 75% of resolved cases
Kade Ariani is an examiner in Tech Center 1600 and Art Unit 1651, having handled 837 resolved cases. The examiner maintains an allowance rate of 74.8 percent. This 74.8 percent rate indicates the frequency of granted patents among the 837 resolved cases. Practitioners can use these figures to evaluate the prosecution environment and the likelihood of success in this technology area.
The interview lift is 32.6 percent, which is a statistic that shows the change in allowance probability following an interview. This 32.6 percent lift is a notable metric for developing a strategy. The median days to allowance is 1030, providing a benchmark for the time required to reach a grant. This 1030-day median is a key data point for managing expectations. These figures from Tech Center 1600 and Art Unit 1651 serve as the basis for understanding the examiner's historical performance and the duration of the prosecution cycle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18715107 | LEUCONOSTOC MESENTEROIDES CJLM119 STRAIN, AND FOOD FERMENTATION COMPOSITION COMPRISING CULTURE PRODUCT THEREOF | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18279192 | FERMENTED APPLE COMPOSITION | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18572429 | COMPOSITIONS AND METHODS USING A COMBINATION OF AT LEAST ONE FIBER AND AT LEAST ONE PROBIOTIC TO IMPROVE MICROBIOME RESILIENCE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18961073 | COMPOSITIONS AND METHODS FOR C. DIFFICILE TREATMENT | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18849210 | COMBINATION DRUG FOR TREATING MALIGNANT TUMOR | Non-Final OA | RIKEN |
| 18816776 | LIGILACTOBACILLUS PROBIOTICS, LIGILACTOBACILLUS EXTRACELLULAR VESICLES AND METHODS OF USING SAME | Non-Final OA | UNIVERSITY OF OTTAWA |
| 18960342 | DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENT | Non-Final OA | Baylor College of Medicine |
| 18829900 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18723470 | Microbial communities | Non-Final OA | Universiteit Gent |
| 18038067 | GLYCOSIDE PRODUCT BIOSYNTHESIS AND RECOVERY | Non-Final OA | Manus Bio Inc. |
| 18695069 | Sample Preparation and Detection Methods Using Enzymatic Digestion | Non-Final OA | Neogen Corporation |
| 18574232 | METHODS OF COLONIZING A MICROBIOME, TREATING AND/OR PREVENTING INFLAMMATORY BOWEL DISEASE AND GRAFT VERSUS HOST DISEASE | Non-Final OA | Vedanta Biosciences, Inc. |
| 18255420 | PRODUCTION OF FUNGAL BIOMASS | Final Rejection | MUSHLABS GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy